Curasight (CURAS) investor relations material

Executive summary

• Advanced uPAR-targeted theranostic platform with progress in both uTREAT® therapy and uTRACE® diagnostics, including promising preliminary Phase 1 data in high-grade gliomas.

• Board strengthened with two experienced international healthcare leaders, enhancing expertise in radioligand therapy and commercialization.

• Increased visibility through participation in major healthcare conferences and strategic investor engagement.

• Internal ownership restructuring consolidating co-founders' holdings, now held by Curacap II ApS at 28.33%.

• Partial conversion of DKK 25 million convertible loan, reducing debt, issuing 429,363 new shares, and broadening long-term shareholder base.

Financial highlights

• Q1 2026 gross loss: kDKK -13,078 (vs. kDKK -4,699 year-over-year); operating loss: kDKK -15,278 (vs. kDKK -6,209); loss before tax: kDKK -16,704 (vs. kDKK -6,579); loss for the period: kDKK -15,329 (vs. kDKK -5,204).

• Total assets at March 31, 2026: kDKK 36,246 (vs. kDKK 17,660 year-over-year); equity ratio: 19.0% (vs. 14.2%).

• Cash at March 31, 2026: kDKK 22,088, plus mDKK 15 loan facility, totaling mDKK 37.

• Earnings per share: DKK -0.32 (vs. DKK -0.25 year-over-year).

• Market cap approx. mDKK 773 (DKK 16 per share); share price up 343% year-over-year.

Outlook and guidance

• Topline results from Phase I uTREAT® trial in glioblastoma expected Q3 2026; preliminary efficacy data expected Q2 2026.

• uTRACE® prostate cancer results expected H2 and Q4 2026.

• Focus remains on advancing clinical development of uTREAT® and uTRACE®, with key milestones and patient enrollment in 2026.

• Regulatory milestones for uTREAT® in H2 2025.

• Anticipates increased strategic and commercial interest in radiopharmaceuticals.